Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia.

Kanematsu M, Morimoto M, Honda J, Nagao T, Nakagawa M, Takahashi M, Tangoku A, Sasa M.

BMC Cancer. 2011 Oct 10;11:436. doi: 10.1186/1471-2407-11-436.

2.

Exemestane for breast-cancer prevention in postmenopausal women.

Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H; NCIC CTG MAP.3 Study Investigators..

N Engl J Med. 2011 Jun 23;364(25):2381-91. doi: 10.1056/NEJMoa1103507. Epub 2011 Jun 4. Erratum in: N Engl J Med. 2011 Oct 6;365(14):1361.

3.

Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.

Freedman AN, Yu B, Gail MH, Costantino JP, Graubard BI, Vogel VG, Anderson GL, McCaskill-Stevens W.

J Clin Oncol. 2011 Jun 10;29(17):2327-33. doi: 10.1200/JCO.2010.33.0258. Epub 2011 May 2. Erratum in: J Clin Oncol. 2013 Nov 10;31(32):4167.

4.

Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial.

LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, Margolis KL, Stefanick ML, Brzyski R, Curb JD, Howard BV, Lewis CE, Wactawski-Wende J; WHI Investigators..

JAMA. 2011 Apr 6;305(13):1305-14. doi: 10.1001/jama.2011.382.

5.

Breast cancer risk in relation to the interval between menopause and starting hormone therapy.

Beral V, Reeves G, Bull D, Green J; Million Women Study Collaborators..

J Natl Cancer Inst. 2011 Feb 16;103(4):296-305. doi: 10.1093/jnci/djq527. Epub 2011 Jan 28.

6.

New and translational perspectives of oestrogen deprivation in breast cancer.

Dunbier AK, Martin LA, Dowsett M.

Mol Cell Endocrinol. 2011 Jul 4;340(2):137-41. doi: 10.1016/j.mce.2010.12.034. Epub 2011 Jan 19. Review.

PMID:
21255630
7.

Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.

Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL; WHI Investigators..

JAMA. 2010 Oct 20;304(15):1684-92. doi: 10.1001/jama.2010.1500.

8.

Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancer.

Reding KW, Doody DR, McTiernan A, Hsu L, Davis S, Daling JR, Porter PL, Malone KE.

Breast Cancer Res Treat. 2011 Apr;126(3):749-61. doi: 10.1007/s10549-010-1174-7. Epub 2010 Sep 29.

9.

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ; American Society of Clinical Oncology..

J Clin Oncol. 2010 Aug 10;28(23):3784-96. doi: 10.1200/JCO.2009.26.3756. Epub 2010 Jul 12. Review.

PMID:
20625130
10.

Menopause-related workload in general practice 1996-2005: a retrospective study in the UK.

Iversen L, Delaney EK, Hannaford PC, Black C.

Fam Pract. 2010 Oct;27(5):499-506. doi: 10.1093/fampra/cmq038. Epub 2010 Jun 7.

PMID:
20530133
11.

Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy.

Chlebowski RT, Anderson G, Manson JE, Pettinger M, Yasmeen S, Lane D, Langer RD, Hubbell FA, McTiernan A, Hendrix S, Schenken R, Stefanick ML.

J Clin Oncol. 2010 Jun 1;28(16):2690-7. doi: 10.1200/JCO.2009.24.8799. Epub 2010 May 3.

12.

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL 3rd, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project..

Cancer Prev Res (Phila). 2010 Jun;3(6):696-706. doi: 10.1158/1940-6207.CAPR-10-0076. Epub 2010 Apr 19.

13.

Hormone therapy and fatal breast cancer.

Norman SA, Weber AL, Localio AR, Marchbanks PA, Ursin G, Strom BL, Weiss LK, Burkman RT, Bernstein L, Deapen DM, Folger SG, Simon MS, Nadel MR.

Pharmacoepidemiol Drug Saf. 2010 May;19(5):440-7. doi: 10.1002/pds.1941.

14.

Postmenopausal estrogen and progestin effects on the serum proteome.

Pitteri SJ, Hanash SM, Aragaki A, Amon LM, Chen L, Busald Buson T, Paczesny S, Katayama H, Wang H, Johnson MM, Zhang Q, McIntosh M, Wang P, Kooperberg C, Rossouw JE, Jackson RD, Manson JE, Hsia J, Liu S, Martin L, Prentice RL.

Genome Med. 2009 Dec 24;1(12):121. doi: 10.1186/gm121.

15.

Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women's health initiative randomized trial.

McTiernan A, Chlebowski RT, Martin C, Peck JD, Aragaki A, Pisano ED, Wang CY, Johnson KC, Manson JE, Wallace RB, Vitolins MZ, Heiss G.

J Clin Oncol. 2009 Dec 20;27(36):6135-43. doi: 10.1200/JCO.2008.21.7166. Epub 2009 Nov 9.

16.

Mammographic screening and risk factors for breast cancer.

Cook NR, Rosner BA, Hankinson SE, Colditz GA.

Am J Epidemiol. 2009 Dec 1;170(11):1422-32. doi: 10.1093/aje/kwp304. Epub 2009 Oct 29.

17.

Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study.

Ellis MJ, Gao F, Dehdashti F, Jeffe DB, Marcom PK, Carey LA, Dickler MN, Silverman P, Fleming GF, Kommareddy A, Jamalabadi-Majidi S, Crowder R, Siegel BA.

JAMA. 2009 Aug 19;302(7):774-80. doi: 10.1001/jama.2009.1204.

18.

Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?

Lewis-Wambi JS, Jordan VC.

Breast Cancer Res. 2009;11(3):206. doi: 10.1186/bcr2255. Epub 2009 May 29. Review.

19.

American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.

Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman SM; American Society of Clinical Oncology..

J Clin Oncol. 2009 Jul 1;27(19):3235-58. doi: 10.1200/JCO.2008.20.5179. Epub 2009 May 26.

20.

Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause.

Prentice RL, Manson JE, Langer RD, Anderson GL, Pettinger M, Jackson RD, Johnson KC, Kuller LH, Lane DS, Wactawski-Wende J, Brzyski R, Allison M, Ockene J, Sarto G, Rossouw JE.

Am J Epidemiol. 2009 Jul 1;170(1):12-23. doi: 10.1093/aje/kwp115. Epub 2009 May 25.

Supplemental Content

Support Center